Replies to post #85364 on NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

Excellent points! Supposedly the ClinicalTrials.gov update meant something when it said November 2016 so we should know is two or three days since the bare fact that the trial endpoint has been reached, even if not yet 'scrubbed' is something they can and per their duty to preserve shareholder value should release immediately. So if we hear nothing when the calendar says December, draw your own conclusions.

[Stillwell888]

Jack,

Agree with many of your points but these two sentences are contradictory:

Management on this occasion have maintained a strict radio silence and have not dropped even the smallest of hints of anything re P3 anytime soon. I don't blame management for hyping up expectations on P3.

How can management have hyped expectations on P3 because they are on a "strict radio silence"?

The only ones hyping expectations on it are people on this board who expect a read out in the next few weeks. Perhaps they have better insight then us (and I hope they are right) but I view this as sheer guess work. The only real hint we've had to the efficacy of DCVax-L comes from Dr. Linda Liau and her famous "they are all living longer" quote and the fact she says the proudest achievement in her life is DCVax-L.

As AGM is coming up why not put together a list of questions for it?

[doingmybest]

I would think if NWBO has come this far with their current communication strategy of meeting the minimum legal requirements for a public company, that they will not alter that strategy until they are free from the sensitive regulatory phase they are now in. I do not agree with it from a shareholder perspective but I think that I am being logical in concluding they will not change their communication strategy given where they are right now, until post P3. Then, I expect to see a return to normal interaction.

This company is the most fascinating and frustrating dichotomy of:

- having virtually no market respect for their shares, which reflects on their science and their management

and

- their accomplishments of working with some of the most renown global cancer institutions in the U.S. and the EU
- developing a product that is potentially at the pinnacle of the largest pharma industry challenge and market
- if you do the math the current P3 trial looks like a success

I believe the lack of market respect is due to the checkered and littered history of immuno-oncology and of DC therapy in particular. When technology which is not brand new advances to a breakthrough point it can take significant steps to prove it has truly advanced and this is not just another false alarm. Who would think such a breakthrough would be achieved by NWBO when there are such others in the field with so much more history and resources to place confidence in. If the AF stuff had not occurred they may be in a different place, but, that is what the AF illegal stuff is all about. It has not changed the timeline, just the obstacles to get there. Patients have the most to gain here and the shareholders who have invested with the deepest knowledge possible. Thanks again to real contributors on this board.

Both fascinating and frustrating for a shareholder. GLTA